Navigation Links
CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS

eutics. The Company owns three clinical-stage compounds based on its small molecule "molecular chaperone" co-induction technology. In September 2006, CytRx announced that arimoclomol was shown to be safe and well tolerated at all three doses tested in its Phase IIa clinical trial in patients with ALS. The Company plans to enter a Phase IIb clinical trial with arimoclomol in ALS in the second half of 2007, subject to FDA clearance. Based on preliminary discussions with the FDA, CytRx is now considering a second efficacy clinical trial for ALS, possibly in parallel with the upcoming Phase IIb trial, to provide additional efficacy data to support a possible approval decision by the FDA.

The FDA has granted Fast Track designation and Orphan Drug status to arimoclomol for the treatment of ALS, which has also been granted orphan medicinal product status for the treatment of ALS by the European Commission. The Company has announced plans to commence a Phase II clinical trial for arimoclomol in stroke recovery in the first half of 2008, subject to FDA clearance. The Company has also announced plans to commence a Phase II clinical trial with its next drug candidate, iroxanadine, for diabetic foot ulcers in the first half of 2008, subject to FDA clearance. In addition, the Company plans to open a research and development facility in San Diego in the third quarter of 2007. For more information on the Company, visit www.cytrx.com.

About RXi Pharmaceuticals Corporation

Worcester, Massachusetts-based RXi Pharmaceuticals Corporation, a majority-owned subsidiary of CytRx, is a biopharmaceutical research and development company that focuses on developing RNAi-based therapeutics for the treatment of human disease. RXi's initial focus is on neurodegenerative diseases, oncology, type 2 diabetes and obesity. RXi has licenses to a diverse series of early patents and patent applications that were filed from 1998 to 2006 in the areas of RNAi target sequences, RNAi chem
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:9/2/2014)... 2, 2014 Reportbuyer.com has added a ... and Technologies for Molecular Imaging Devices ... OBJECTIVES The objectives of this study are ... devices used for diagnostic purposes, present global market ... possible market segments as well as forecast market ...
(Date:9/2/2014)... , Sept. 2, 2014 Reportbuyer.com has ... Bariatric Surgery: Global Markets for Services and Devices ... SURGERY Bariatric surgery or weight loss surgery ... variety of processes that deal with the surgical ... or less/noninvasive (endoluminal) and performed in both open ...
(Date:9/2/2014)... NORTHBROOK, Ill. , Sept. 2, 2014 Astellas ... president of intellectual property (IP) in the Americas. Kellerman ... vice president & general counsel at Astellas. In his ... attorneys to partner with the business and manage the ... colleagues. "I am very pleased to ...
Breaking Medicine Technology:Global Markets and Technologies for Molecular Imaging Devices 2Global Markets and Technologies for Molecular Imaging Devices 3Global Markets and Technologies for Molecular Imaging Devices 4Global Markets and Technologies for Molecular Imaging Devices 5Global Markets and Technologies for Molecular Imaging Devices 6Global Markets and Technologies for Molecular Imaging Devices 7Global Markets and Technologies for Molecular Imaging Devices 8Global Markets and Technologies for Molecular Imaging Devices 9Global Markets and Technologies for Molecular Imaging Devices 10Global Markets and Technologies for Molecular Imaging Devices 11Global Markets and Technologies for Molecular Imaging Devices 12Global Markets and Technologies for Molecular Imaging Devices 13Global Markets and Technologies for Molecular Imaging Devices 14Global Markets and Technologies for Molecular Imaging Devices 15Global Markets and Technologies for Molecular Imaging Devices 16Global Markets and Technologies for Molecular Imaging Devices 17Global Markets and Technologies for Molecular Imaging Devices 18Global Markets and Technologies for Molecular Imaging Devices 19Global Markets and Technologies for Molecular Imaging Devices 20Global Markets and Technologies for Molecular Imaging Devices 21Global Markets and Technologies for Molecular Imaging Devices 22Global Markets and Technologies for Molecular Imaging Devices 23Global Markets and Technologies for Molecular Imaging Devices 24Global Markets and Technologies for Molecular Imaging Devices 25Bariatric Surgery: Global Markets for Services and Devices 2Bariatric Surgery: Global Markets for Services and Devices 3Bariatric Surgery: Global Markets for Services and Devices 4Bariatric Surgery: Global Markets for Services and Devices 5Bariatric Surgery: Global Markets for Services and Devices 6Bariatric Surgery: Global Markets for Services and Devices 7Bariatric Surgery: Global Markets for Services and Devices 8Bariatric Surgery: Global Markets for Services and Devices 9Bariatric Surgery: Global Markets for Services and Devices 10Bariatric Surgery: Global Markets for Services and Devices 11Bariatric Surgery: Global Markets for Services and Devices 12
... Sept. 2 NewCardio (OTC Bulletin Board: NWCI ... Renz, Jr., NewCardio,s President and CEO, purchased 128,000 shares during ... weeks following the Company,s filing of its SEC Form 10-Q ... 2010. "As discussed on our August 12, ...
... SKILLMAN, N.J., Sept. 2 ConvaTec, a world-leading developer ... hospital care, announced today the introduction of a new, ... with Strengthening Fibers, now available in the U.S. and ... highly exuding chronic and acute wounds. The new dressing, ...
Cached Medicine Technology:NewCardio CEO Increases Equity Position 2NewCardio CEO Increases Equity Position 3NewCardio CEO Increases Equity Position 4ConvaTec Expands AQUACEL® Dressing Product Line With Introduction of New Ribbon Dressing 2ConvaTec Expands AQUACEL® Dressing Product Line With Introduction of New Ribbon Dressing 3ConvaTec Expands AQUACEL® Dressing Product Line With Introduction of New Ribbon Dressing 4
(Date:9/2/2014)... 2014 Medex Analytic Services ... corporate headquarters in Coral Springs, Fla. due to their ... business development objectives for the 2014 year by distinguishing ... industry has requested a higher level of service and ... has delivered, and the industry has responded.” , The ...
(Date:9/2/2014)... By Kathleen Doheny ... -- The U.S. obesity epidemic is a driving force behind ... new study. Researchers looked at data from five national ... the increase in diabetes over time could be explained by ... in U.S. adults. The investigators found that the prevalence ...
(Date:9/2/2014)... 2014 (HealthDay News) -- Melatonin supplements did not reduce ... a new study found. Many older hospital patients ... to disruption of their normal sleep-wake cycle. A lack ... contributes to delirium, but there has been little research ... This study included 378 patients, average age 84, who ...
(Date:9/2/2014)... and marijuana may lead to different types of harmful ... analyzed 2007 to 2011 data gathered from more than ... used alcohol or marijuana at least once. The ... unsafe driving, damage to relationships with friends and romantic ... of alcohol, especially among females. On the ...
(Date:9/2/2014)... LEBANON, NH Doctors trained in locations with less ... better at making clinical decisions that spare patients unnecessary ... in JAMA Internal Medicine . , "Growing concern ... spurred interest in assessing physicians, ability to avoid the ... of the VA Outcomes Group and The Dartmouth Institute ...
Breaking Medicine News(10 mins):Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2Health News:Residency training predicts physicians' ability to practice conservatively 2
... Network,a national organization formed to halt the US ... holding a press conference in Wichita, Kansas,outside the ... for an,emergency order to protect Kansas patients from ... http://doctordeluca.com/Library/WOD/WPS16-Schneider/PrnVsKansas-Complet ,e.zip, Siobhan Reynolds, President ...
... A study from the Jichi Medical University in ... endoscope provided images that clearly identified depressed-type early gastric ... The study appears in the February issue of Gastrointestinal ... Society for Gastrointestinal Endoscopy. , Gastric cancer is ...
... Opportunity with Kentucky-based PrimaryPlus Marks First FQHC Sale, ... Technologies,Inc., a leading provider of integrated electronic health ... that it,has completed a strategic sale in the ... PrimaryPlus of Lewis County, Ky., comes,on the heels ...
... Baltimore ... market, OWINGS ... that Medifast Franchise Systems has sold its,first franchise of Medifast Weight Control ... Centers in the Greater,Baltimore Metropolitan Area., The entire build-out process will ...
... Previous work from this group of scientists, led by ... from flu infection left mice unusually vulnerable to infection ... receptors on immune cells in the lung. These signals ... the lung that help destroy the bugs. But in ...
... made from metals and organic compounds is changing the face ... after its discovery, with applications already in safe storage of ... is aiming to capitalise on core strengths in the field ... skills required within a coherent research network, following a major ...
Cached Medicine News:Health News:Pain Relief Network Sues to Halt Government Actions Taken Against Kansas Patients 2Health News:Optimal band imaging with endoscopy facilitates the diagnosis of depressed-type early gastric cancer 2Health News:Optimal band imaging with endoscopy facilitates the diagnosis of depressed-type early gastric cancer 3Health News:Greenway Medical Technologies Broadens Sales Efforts With Entrance Into Federally Qualified Health Center Marketplace 2Health News:Greenway Medical Technologies Broadens Sales Efforts With Entrance Into Federally Qualified Health Center Marketplace 3Health News:Medifast Franchise Systems Sells First Territory in Baltimore 2Health News:Medifast Franchise Systems Sells First Territory in Baltimore 3Health News:Novel organic metal hybrids that will revolutionize materials science and chemical engineering 2
... site introduces the DiamondTome™ Skin Resurfacing ... unique DiamondTome™ Wands, an evolution in ... to smoother, more youthful skin. , ... the benefits of DiamondTome's™ innovative approach ...
... is a state-of-the-art hair reduction and ... specially designed for use within a ... features and economy in a single ... treatment of unwanted hair, photo rejuvenation ...
... Start or expand your aesthetic practice ... SR, the cost-effective system that's gentle, powerful ... seeking the exciting benefits of IPL Skin ... system promises to be an indispensable tool ...
Standard Lipo-tubing...
Medicine Products: